Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

TreeHouse Foods Faces Slowdown as Shoppers Cut Back on Even Cheaper Groceries

by Team Lumida
March 5, 2025
in Health and Longevity
Reading Time: 4 mins read
A A
0
high-angle photography of grocery display gondola

Photo by Peter Bond on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • TreeHouse Foods, a major supplier of private-label goods for retailers like Walmart and Target, is experiencing slower sales growth as inflation-weary consumers reduce spending on lower-cost groceries.
  • The company is focusing on cost-cutting measures, including supply-chain efficiencies and product adjustments, to protect margins in a challenging demand environment.
  • TreeHouse is expanding selectively through acquisitions while exiting less profitable product lines to streamline operations.
  • Analysts emphasize the need for operational improvements after recent production issues and recalls.

What Happened?

TreeHouse Foods, a leading manufacturer of private-label products for major retailers, is seeing a slowdown in sales growth as inflation-strained consumers cut back on even lower-cost grocery items. While private-label goods gained popularity during the pandemic and inflationary periods, demand has softened recently, with unit sales in key categories growing just 0.6% in late 2024 compared to 4.5% growth earlier in the year. In response, TreeHouse is implementing cost-saving measures, such as automating production processes and renegotiating supplier contracts, to reduce supply-chain costs by $250 million by 2027. The company is also refining its product portfolio, exiting less profitable areas like ready-to-drink beverages while expanding in others, including coffee and tea, through strategic acquisitions.


Why It Matters?

The slowdown in private-label sales reflects broader consumer behavior shifts as inflation continues to pressure household budgets. For investors, this signals potential headwinds for companies reliant on discretionary spending, even in traditionally resilient sectors like groceries. TreeHouse’s focus on cost control and profitability over aggressive sales growth highlights the challenges of navigating a softer demand environment. Additionally, operational missteps, such as production delays and product recalls, have weighed on the company’s performance, underscoring the importance of execution in maintaining investor confidence.


What’s Next?

TreeHouse plans to continue its cost-cutting initiatives while selectively expanding into high-growth areas like coffee and tea. The company’s ability to streamline operations and avoid further production issues will be critical to stabilizing its performance. Analysts expect slower growth in the near term, with TreeHouse forecasting a 3.5% decline in adjusted net sales for the first quarter of 2025. Investors should monitor the company’s progress in improving operational efficiency, managing its product portfolio, and adapting to evolving consumer spending patterns.

Source
Previous Post

China Strikes Back: Tariffs and Export Controls Escalate U.S.-China Trade War

Next Post

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

Recommended For You

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
2 weeks ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
2 weeks ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
2 weeks ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
3 weeks ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more

Healthcare Roundup: Medicare Advantage Gets a $13B Boost, Drug Tariffs Hit 100%, and Wegovy Goes Discount

by Team Lumida
3 weeks ago
person sitting while using laptop computer and green stethoscope near

A packed week in healthcare: Medicare Advantage rates came in at a better-than-expected 2.48% increase, Trump unveiled 100% tariffs on some brand-name drugs, Gilead and Neurocrine spent $8B...

Read more

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
3 weeks ago
doctor holding red stethoscope

A new WSJ analysis breaks down the structural forces behind America's sky-high healthcare costs — from monopoly hospitals and unregulated drug prices to administrative bloat and physician salaries...

Read more

Genetic Tests Come Under Federal Scrutiny as Trump Administration Targets Lab Fraud

by Team Lumida
3 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The CMS has opened a public comment period on how to curb fraudulent genetic testing billing — a billion-dollar problem involving unnecessary tests marketed directly to consumers and...

Read more

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
4 weeks ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
4 weeks ago

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
4 weeks ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more
Next Post
blue UTP cord

$2 Billion Loan Fuels Massive AI Data Center in Utah Amid Surging Demand

gold and black metal tool

Gold Surges as Trade War Escalation Drives Demand for Safe-Haven Assets

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

white and black concrete building

Nike CEO Secures NFL Partnership Through 2038, Signaling Return to Sports-First Strategy

February 7, 2025
AI Security Breach: How Hackers Stole OpenAI’s Internal Secrets

Microsoft, OpenAI Truce Clears Hurdle in Path to For-Profit Conversion

September 12, 2025
a computer keyboard with a blue light on it

California’s AI Bill: What Business Tech Leaders Are Saying

September 25, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018